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A B S T R A C T   
Visual short-term memory (VSTM) deficits including VSTM binding have been associated with Alzheimer’s 
disease (AD) from preclinical to dementia stages, cross-sectionally. Yet, longitudinal investigations are lacking. 
The objective of this study was to evaluate VSTM function longitudinally and in relation to expected symptom 
onset in a cohort of familial Alzheimer’s disease. Ninety-nine individuals (23 presymptomatic; 9 symptomatic 
and 67 controls) were included in an extension cross-sectional study and a sub-sample of 48 (23 presymptomatic 
carriers, 6 symptomatic and 19 controls), attending two to five visits with a median interval of 1.3 years, 
included in the longitudinal study. Participants completed the “What was where?” relational binding task (which 
measures memory for object identification, localisation and object-location binding under different conditions of 
memory load and delay), neuropsychology assessments and genetic testing. Compared to controls, presymp-
tomatic carriers within 8.5 years of estimated symptom onset showed a faster rate of decline in localisation 
performance in long-delay conditions (4s) and in traditional neuropsychology measures of verbal episodic 
memory. This study represents the first longitudinal VSTM investigation and shows that changes in memory 
resolution may be sensitive to tracking cognitive decline in preclinical AD at least as early as changes in the more 
traditional verbal episodic memory tasks.   
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1. Introduction 
Progressive episodic memory impairment is a central, defining 
feature of Alzheimer’s disease (AD) (Dubois et al., 2007; McKhann et al., 
1984). Deficits in short-term memory (STM), the ability to temporarily 
maintain information over seconds (Atkinson and Shiffrin, 1968, 1971), 
have been relatively less well studied. Classically, STM has been tested 
using ‘span’ measures where participants are asked to remember a string 
of stimuli (Groeger et al., 1999). Although such quantal (discrete) 
measures have been fundamental to developing our understanding of 
memory function, they are not as sensitive to detect changes in memory 
resolution due to the binary nature of responses measured (correct vs 
incorrect recall). In 2014, Ma and colleagues (Ma et al., 2014) proposed 
a new approach to study the resolution with which items are retained, 
arguing that just because an individual fails to recall an item correctly 
this does not imply they had no memory of it at all. 
Delayed-reproduction tasks (e.g. (Peich et al., 2013; Pertzov et al., 2012, 
2013)) rely on remembering a feature and reproducing the exact stored 
features after a retention period using a continuous analogue response 
space (Bays et al., 2009; Gorgoraptis et al., 2011; Liang et al., 2016). In 
recent studies, delayed-reproduction tasks have been reported to be 
more sensitive than conventional span measures of STM, especially in 
clinical populations (Zokaei et al., 2015). 
The concept of ‘preclinical AD’ continues to evolve and is subject to 
debate, but current clinical criteria at least on a research basis, allow for 
it to be diagnosed in asymptomatic individuals without evidence for 
objective cognitive decline (Sperling et al., 2011) but with accumulation 
of β-amyloid (Aβ) (Jack and Holtzman, 2013). Developing a better un-
derstanding of the preclinical changes of AD and improving methods for 
early detection may offer the best chance for therapeutic success, before 
irreversible neuronal loss has occurred. 
One important line of research has suggested that the ability to bind 
object features together in visual short-term memory (VSTM) is critically 
affected in AD (Della Sala et al., 2012; Parra et al. 2009, 2010a, 2011, 
2011; Pavisic et al., 2020a). Interest in these tasks increased when 
studies suggested impairments could be detected at preclinical stages of 
the condition, more sensitively than other traditional memory measures 
(Parra et al., 2010b). A study by Liang and colleagues found deficits for 
object-location binding and localisation of the target position in pre-
symptomatic familial Alzheimer’s disease (FAD) carriers, in the most 
challenging task conditions (highest load and longest delay for 
object-location binding and highest-load across delays for localisation of 
the target position (Liang et al., 2016)). FAD is an autosomal dominant 
condition caused by mutations in either presenilin 1 (PSEN1), presenilin 
2 (PSEN2) or amyloid precursor protein (APP) (Ryan et al., 2016) and its 
pathogenic mutations in these genes are nearly 100% penetrant (Ryman 
et al., 2014). FAD shares many features (i.e. clinical, radiological and 
histopathological) with sporadic AD (Rossor et al., 1996; Ryan and 
Rossor, 2010) and the age at onset in FAD is reasonably similar between 
family members, making this cohort particularly valuable to the study of 
preclinical stages of AD (Ryman et al., 2014). 
In light of these findings, a number of questions remain unanswered:  
1. Are the cross-sectional preclinical deficits in VSTM also reflected in 
longitudinal task performance?;  
2. Given that an individual’s expected age at symptom onset may be 
estimated from their parental onset, what is the relationship between 
an individual’s VSTM performance and proximity to expected years 
to onset (EYO) at the time of testing?; And finally, for comparison: 
3. Is longitudinal cognitive decline in presymptomatic and symptom-
atic mutation carriers seen in other more traditional neuropsy-
chology tasks? 
We wished therefore first to extend the work of Liang and colleagues 
(Liang et al., 2016) in a larger sample and secondly to explore how 
VSTM in both presymptomatic and symptomatic FAD mutation carriers, 
changed with EYO. Finally, for comparison we evaluate longitudinal 
decline in traditional neuropsychology tasks. To our knowledge, no 
other study has examined VSTM functions longitudinally in a preclinical 
cohort such as FAD. 
2. Methods 
2.1. Study design and participants 
Participants were recruited from the ongoing longitudinal FAD study 
at the Dementia Research Centre, University College London, which 
receives referrals from across the UK, if they had an autosomal dominant 
family history of AD and a known pathological mutation in PSEN1 or 
APP genes in at least one affected family member. Healthy individuals 
(without a family history of AD) were also recruited to the study from 
our research database. Inclusion criteria also required participants to 
have normal or corrected-to-normal visual acuity and colour vision and 
≥70% average accuracy in identification performance at baseline visit 
(see (Liang et al., 2016)). 
Mutation analysis was carried out using Sanger sequencing (Janssen 
et al., 2003; Ryan et al., 2016). Genetic results were available for all 
at-risk individuals, on either a clinical or a research basis. Research 
genetic results were only shared with the statistician involved in the 
study and were not disclosed to the participants or to other researchers 
who remained blind to whether presymptomatic individuals were mu-
tation carriers or non-carriers. 
Consequently, the study included symptomatic carriers, presymp-
tomatic carriers and controls: symptomatic individuals were mutation 
carriers who had cognitive symptoms consistent with AD; presymp-
tomatic individuals were mutation carriers who had not developed 
symptoms and who scored zero on the Clinical Dementia Rating (CDR) 
scale (Morris, 1993) and control participants consisted of both 
non-carriers (at-risk individuals who tested negative for pathological 
mutations) and healthy individuals (from our research database). As per 
Liang and colleagues, we used EYO as an approximation of how far in-
dividuals (presymptomatic and symptomatic) were from symptom onset 
(Liang et al., 2016). This was based on an individuals’ age at the time of 
assessment subtracted from the age at which their affected parent 
developed symptoms (Bateman et al., 2012; Ryman et al., 2014) with a 
positive value indicating years from/post onset and a negative value 
indicating years to/pre onset. Similar to previous FAD studies (Weston 
et al., 2020), we carried out an exploratory analysis whereby PMCs were 
separated into those furthest away and those closest from expected onset 
using the median value of EYO of PMCs in our dataset (8.5 years before 
onset). This resulted in the following four groups based on a partici-
pant’s status at the baseline assessment: symptomatic carriers; ‘early’ 
presymptomatic mutation carriers (PMCs) (more than 8.5 years from 
expected onset), ‘late’ PMCs (less than 8.5 years from expected onset) 
and controls. This was done recognizing that subtle cognitive changes 
occur even at presymptomatic stages of FAD (e.g. (O’Connor et al., 
2020)) and that by isolating PMCs closest to onset, subtle cognitive 
deficits would be more pronounced than in PMCs furthest away from 
expected onset. 
In addition, we also considered how performance varied continu-
ously with a) EYO (for all FAD carriers: symptomatic and presymp-
tomatic) and b) actual years to/from symptom onset (AYO) for 
symptomatic carriers (N = 6) and PMCs who converted into symptom-
atic carriers throughout the study (N = 3). Actual age at onset was 
defined as the age at which progressive symptoms of FAD were first 
noticed by the individual or someone who knew the patient well. 
The cross-sectional analysis included 99 individuals: 67 controls (16 
non-carrier siblings) and 32 mutation carriers, 9 of whom were symp-
tomatic. Differences between our cross-sectional study and Liang and 
colleagues (Liang et al., 2016) were: the addition of n = 17 at-risk 
(mutation carriers and non-carriers) individuals; n = 1 symptomatic 
carrier and the exclusion of n = 1 at-risk individual (see Supplementary 
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Materials, Fig. e1, for details). Note that mutation status of these at-risk 
individuals is not disclosed to prevent unblinding of genetic status. 
The longitudinal analysis included 48 participants who attended 
between 2 and 5 visits (median 3), at intervals ranging from 0.5 to 3.9 
years (median 1.3): 19 controls (12 non-carrier siblings) and 29 muta-
tion carriers, 6 of whom were symptomatic from the first assessment. 
(Mean follow-up time: controls = 2.8 [SD 1.7] years, range = 1–6; early 
PMCs = 3.7 [1.7] years, range = 1–6 years; late PMCs = 3.4 [1.7] years, 
range = 1–6; symptomatic carriers = 2.6 [0.7] years, range = 2–4)). 
All subjects provided written informed consent to participate. The 
study was approved by The National Hospital for Neurology and 
Neurosurgery and Institute of Neurology Joint Research Ethics Com-
mittee (subsequently, National Research Ethics Service Committee, 
London Queen Square, Research Ethics Committee ref 11/LO/0753). 
2.2. Protocol 
The study protocol included a clinical and neuropsychological 
assessment and the “What was where?” VSTM experiment (Pertzov 
et al., 2012). Detailed interviews were conducted with individuals 
at-risk of FAD and their close informants to assess for the presence of 
cognitive or behavioural symptoms attributable to AD. AD was diag-
nosed in accordance with the Dubois criteria (Dubois et al, 2007, 2010). 
Folstein’s mini-mental state examination (MMSE) (Folstein et al., 1975), 
the CDR (Morris, 1993) and Hospital Anxiety and Depression scale 
(Zigmond and Snaith, 1983) were administered. 
The neuropsychological test battery included measures of several 
cognitive domains: episodic memory (recognition memory test (RMT) 
for words and faces (Warrington, 1996)); working memory (digit span 
(Wechsler, 1987)); intellectual function (Wechsler Abbreviated Scale of 
Intelligence (WASI) (Wechsler, 1999)); executive function (Stroop 
(1935)); confrontational naming (graded naming test (McKenna and 
Warrington, 1983); vocabulary (British picture vocabulary scale (BPVS) 
(Dunn and Dunn, 2009)); arithmetic (Graded Difficulty Arithmetic Test 
(GNT) (Jackson and Warrington, 1986)), visual perception (object de-
cision test from the visual object and space perception (VOSP) battery 
(Warrington and James, 1991)); processing speed (digit symbol test 
(Wechsler and De Lemos, 1981)) and estimated premorbid intelligence 
(the National Adult Reading Test) (NART) (Law and O’Carroll, 1998; 
Nelson, 1991) (Table 1). 
“What was where?” has been described in previous publications 
(Liang et al., 2016; Pertzov et al., 2012). A depiction of the task is shown 
in Fig. 1. Participants sat approximately 42 cm in front of an interactive 
touch-sensitive screen (Dell Inspiron One 2320) with a 1920 ×
1080-pixel matrix corresponding to approximately 62 × 35◦ of visual 
angle. In each trial, participants viewed 1 or 3 fractal objects, each 
randomly located on the screen and were asked to remember both the 
object’s identity and their locations. A blank screen was then displayed 
for a 1 or 4seconds (s) duration, followed by a test array in which two 
fractals appeared along the vertical meridian. One of these was in the 
previous memory array (the target fractal) whereas the other one was a 
foil (distractor). The foil was not an unfamiliar object, but was part of 
the general pool of fractal images presented throughout the experiment. 
All objects including the foils were drawn from a pool of 60 fractals that 
were used across the experiment (rendered using http://sprott.physics. 
wisc.edu/fractals.htm). Participants were required to select the fractal 
they remembered from the memory array and drag it to its location. This 
provided a continuous measure of localisation error. Each participant 
performed a practice block of 10 trials (not included in the analysis) 
followed by two test blocks each consisting of 10 trials with 1 fractal and 
40 trials with 3 fractals, with a balanced number of trials with 1s or 4s 
delay between memory and test arrays. 
In this paper, findings focus on three outcomes which were included 
in the previous cross-sectional study (Liang et al., 2016):  
• Identification performance: proportion of trials where the correct 
object was chosen.  
• Localisation error: the distance (in degrees of visual angle) between 
the centre of the target object once placed in its remembered location 
and its true (original) location in the memory array (only correctly 
identified objects). 
Table 1 
Baseline demographics, neuropsychology and VSTM performance by participant 







(N = 11) 
Symptomatic 
carriers (N = 9) 
Demographics 
Sex: N (%) Male 34 (50.7) 3 (25.0) 7 (63.6) 6 (66.7) 
Age (yrs) 39.4 (8.1) 34.8 (6.4) 37.0 (5.0) 48.1 (9.8)* 
EYO (yrs) NA − 12.9 
(4.7) 
− 5.8 (1.8) 3.0 (4.1) 
AYO (yrs) NA NA NA 3.1 (4.0) 
Education (yrs) 15.4 (2.7) 14.3 (2.5) 13.3 (2.5) 
* 
13.9 (2.9) 
MMSE 29.5 (0.8) 29.3 (0.9) 29.5 (0.8) 25.1 (3.7)** 
CDR global 0.0 (0.0) 0.0 (0.0) 0.0 (0.0) 0.6 (0.2)** 
Anxiety 6.1 (3.8) 7.9 (4.6) 3.9 (3.9)* 7.0 (4.5) 
Depression 3.2 (2.8) 2.9 (4.0) 1.3 (1.6)* 2.4 (2.1) 
Neuropsychology tests 
















16.7 (6.8) 13.9 (5.0) 14.3 (4.6) 10.3 (5.8)** 
RMT faces 41.1 (7.2) 41.0 (4.2) 43.8 (4.5) 40.3 (3.7) 
RMT words 47.0 (5.0) 48.7 (2.2) 46.5 (2.8) 35.3 (10.0)** 
Digit span 
forwards/8 
7.1 (1.2) 6.8 (1.0) 7.4 (1.1) 6.0 (1.5)* 
Digit span 
backwards/7 
5.2 (1.2) 5.7 (1.3) 5.4 (1.1) 4.3 (1.6) 





GNT/30 20.9 (4.6) 17.8 (5.8) 19.2 (5.4) 18.8 (7.2) 





VOSP OD/20 18.0 (2.8) 17.8 (1.8) 18.3 (1.3) 17.6 (1.5) 




Identification (% correct) 
Overall 91.6 (4.8) 90.2 (6.3) 92.0 (3.9) 81.9 (5.0)** 
Localisation error (deg) 
Overall 4.4 (1.3) 4.5 (1.3) 4.6 (1.1) 7.8 (1.8)** 
Swap error (%) 
Overall 10.6 (5.3) 11.7 (4.7) 10.2 (5.9) 22.6 (8.1)** 
Block 1, 1s delay 12.0 (8.4) 12.4 (9.2) 9.9 (5.0) 21.2 (12.6) 
Block 1, 4s delay 13.2 (8.7) 18.7 (9.2) 15.0 
(10.8) 
23.2 (18.0)* 
Unadjusted mean values are given with SD unless otherwise stated. SD = stan-
dard deviation; NA = not applicable; PMC = presymptomatic mutation carrier; 
EYO = estimated years to/from symptom onset (a negative value indicates a 
younger age than their estimated age at symptom onset); AYO = actual years to/ 
from onset (positive values indicate years post onset); Anxiety and depression 
scores from HADS = hospital anxiety and depression scale; IQ = intelligence 
quotient; MMSE = mini mental state examination; CDR = clinical dementia 
rating scale; RMT = recognition memory test; GNT = graded naming test; VOSP 
OD = object decision from the visual object and space perception battery. Digit 
spans forwards and backwards are taken from the WMS-R ¼ Wechsler Memory 
Scale. Neuropsychology data were available at baseline for: 64 participants for 
performance IQ, verbal IQ; 98 for arithmetic total, GNT, NART, VOSP; 99 for 
RMT faces, RMT words, digit span forwards, digit span backwards; 71 for BPVS; 
and 78 for Stroop (s). Bold = significant; *: the difference between the patient 
group and controls for that variable was significant at p < 0.05; **: the difference 
between the patient group and controls for that variable was significant at p <
0.01. 
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• Swap errors: the percentage of correctly identified objects placed 
within 4.5 deg eccentricity of other fractals in the original array-3- 
item condition only (object-location binding). In accordance with 
previous studies (Liang et al., 2016; Pertzov et al., 2012), a threshold 
of 4.5 deg was used as objects were never presented less than 9 deg 
from each other in the memory array and therefore an object could 
not be swapped with more than one object. 
Liang and colleagues also examined the “Nearest item control (NIC)”: 
an index of localisation precision regardless of object identity, calcu-
lated as the distance between the centre of the target object once placed 
in its remembered location and the centre of the nearest location in the 
memory array –whichever item that was, i.e., it is agnostic to the 
identity of the nearest fractal. It provided a measure of localisation error 
discounting the effects of swap errors for the 3-items condition only 
(Liang et al., 2016; Pertzov et al., 2013). Results for this outcome are 
provided in the Supplementary Materials (section 2.2). 
2.3. Statistical analysis 
Due to a skewed distribution the absolute localisation error was log 
transformed and proportion of swap errors was square root transformed 
before analysis. 
2.3.1. Cross-sectional analysis 
As an extension study, data was initially analysed cross-sectionally. 
Baseline demographics and neuropsychology scores were compared 
between controls and each of symptomatic carriers, early PMCs and late 
PMCs using ANOVA, or Kruskal-Wallis test where the distribution of the 
variable was skewed. Fishers’ exact test was used to compare the sex 
distribution between the groups. 
VSTM performance at the baseline visit was compared between 
controls and each of symptomatic carriers, early PMCs and late PMCs 
using logistic regression models for object identity and linear regression 
model for all other measures. Robust standard errors were used to ac-
count for repeated measures. Models were adjusted for delay (1 vs 4s), 
block (1 vs 2), number of items (1 vs 3, where relevant), sex, age at 
baseline, and NART at baseline. Interaction tests were used to examine 
whether group differences in performance, varied by delay, block and 
number of items. 
2.3.2. Longitudinal analysis 
In order to evaluate VSTM function longitudinally, change over time 
in VSTM was investigated in three ways: i) comparison of rate of change 
in VSTM performance (for each metric) between controls and each of 
symptomatic carriers, early PMCs, late PMCs (with groups defined by 
their status at baseline). Longitudinal change in object identity was 
analysed using a mixed effects logistic regression model and analysis of 
the other VSTM outcomes used a linear mixed effects model. Models 
were adjusted for delay, block, number of items (where relevant), sex, 
age at baseline, and NART at baseline and interaction tests were used to 
examine whether group differences in rates of change in performance 
varied by delay, block and number of items. ii) examination of the as-
sociation between VSTM performance and EYO as a continuous measure 
(in presymptomatic and symptomatic mutation carriers) after adjusting 
for healthy ageing. This was done by including mutation carrier status, 
EYO, EYO squared (in mutation carriers only) and age at visit as pre-
dictors in the model. Including the control data allowed estimation of 
the effect of age at visit across both controls and mutation carriers. The 
rationale for including age at visit was to ensure that any difference 
observed in VSTM performance with increasing EYO could be attributed 
to EYO rather than ageing, since those closer to onset also tend to be of 
older age. This analysis using EYO as a continuous measure was included 
to address limitations associated with categorising the EYO measure-
ment (Altman and Royston, 2006). Iii) examination of association be-
tween VSTM performance and AYO as a continuous measure in the FAD 
participants where this was known (symptomatic carriers at baseline (N 
= 6) and late PMCs who became symptomatic during the study-‘-
converters’: N = 3) after accounting for healthy ageing as for the EYO 
analysis. The rationale for this analysis was that actual, rather than 
expected, years to onset would provide a more precise estimation of how 
VSTM function varies with proximity to onset. As for approach ‘‘i)’, 
object identity was analysed using a mixed effects logistic regression 
model and analysis of the other VSTM outcomes used a linear mixed 
effects model for approaches ‘ii)’ and ‘iii)’. In approaches ‘ii)’ and ‘iii)’, 
for each model the predicted mean difference was calculated for controls 
and by EYO or AYO in the carriers, setting age and NART at the average 
of the sample and for an equal balance of sexes and task conditions and 
Fig. 1. Schematic of “What was there?” (adapted from (Liang et al., 2016) under the terms of the Creative Commons Attribution License (CC BY)).  
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differences between the mean for mutation carriers and the mean in 
controls were also calculated by EYO and AYO. Furthermore, models 
were adjusted for delay, block, number of items (where relevant), sex 
and NART at baseline and interaction tests were used to examine 
whether the association with EYO or AYO (respectively) differed by 
delay, block and number of items. 
Finally, in order to evaluate whether cognitive decline in presymp-
tomatic and symptomatic mutation carriers was seen in other more 
traditional neuropsychology tasks, longitudinal change in neuropsy-
chology performance was compared between controls and each of 
symptomatic carriers, early PMCs and late PMCs. Mixed effects linear 
regression was used for analysis of WASI verbal IQ, WASI performance 
IQ, arithmetic, BPVS, GNT, NART, and Stroop. A mixed effects logistic 
regression model was used for RMT words, RMT faces and VOSP. Mixed 
effects ordinal logistic regression model was used for digit span forwards 
and digit span backwards. All models were adjusted for sex, age at 
baseline, and NART at baseline. 
For all analysis statistical significance was set at p < 0.05 and anal-
ysis performed on Stata v.14 or later. 
See the Supplementary Materials for further details on the statistical 
methods (section 1.2). 
3. Results 
3.1. Cross-sectional analysis for N = 99 
3.1.1. Demographics and traditional neuropsychology 
Baseline characteristics of the groups are presented in Table 1. Sixty- 
seven controls and 32 carriers completed the “What was where?” task 
cross-sectionally. Early PMCs were on average 12.9 years away from 
their expected onset and compared to controls were on average younger 
(t (95) = -1.89, p = 0.062), and had lower scores in: verbal IQ (t (60) =
-2.55, p = 0.013), BPVS (U = 113, p = 0.004) and NART measures (U =
204.5, p = 0.006). Late PMCs were on average 5.8 years before expected 
onset, and compared to controls had lower education (U = 183.5, p =
0.021), lower baseline anxiety (U = 219, p = 0.034) and depression 
scores (U = 205, p = 0.018) and had significantly lower scores for verbal 
IQ (t (60) = -2.78, p = 0.007) but similar scores on remaining measures. 
Symptomatic carriers were on average 3.0 years after expected onset 
and as expected were older than controls (t (95) = 3.11, p = 0.026), had 
lower MMSE (U = 65, p < 0.001) and significantly worse scores on 
neuropsychology tasks including arithmetic (t (94) = -2.74, p = 0.007), 
RMT for words (U = 79, p = 0.001), digit span (U = 158, p = 0.015) and 
Stroop (U = 39, p < 0.001) (Table 1). Additionally, the global CDR score, 
was indicative of cognitive impairments consistent with AD (at a rela-
tively early stage: mean = 0.6 (SD 0.2), range = 0.5–1, Table 1). 
Baseline characteristics of the participants included in the longitu-
dinal study (N = 48) are given in the Supplementary Materials 
(Table e1). 
3.1.2. VSTM performance 
VSTM performance was significantly worse with higher-memory 
load (3 vs 1 item) (odds ratio (OR) for correct identification = 0.20 
[95% CI 0.15, 0.28], Z = − 9.86, p < 0.001; localisation error = 2.82 
times higher [2.65, 3.00], t (97) = 33.1, p < 0.001). Longer delay (4 vs 
1s) was also associated with worse identification performance (OR =
0.82 [CI 0.71, 0.95], Z = − 265, p = 0.008) and localisation performance 
(localisation error = 26.9% greater [21.9%, 32.1%], t (97) = 11.73, p <
0.001) but did not affect swap proportion (difference in √swap error 
proportion = 0.002 [-0.026, 0.030], t (97) = 4.74, p = 0.255). 
Symptomatic carriers had 44.0 [95% CI 25.4, 56.7] % lower odds of 
correctly identifying the target (Z = − 4.08, p < 0.001), 46.0 [20.1, 77.5] 
% greater localisation error (t (97) = 3.85, p < 0.001) and made a 
greater proportion of swap errors (difference in √swap error proportion 
= 0.162 [0.095, 0.231], t (97) = 4.74, p < 0.001) in comparison to 
controls (also see Table 1 for unadjusted mean values). There were no 
significant differences between early PMCs and controls or late PMCs 
and controls (Table 1, Fig. 2). There was no evidence for an interaction 
between group and delay or group and number of items in identification 
(interaction tests across groups: delay Х2 (3) = 4.34, p = 0.227; items 
(Х2 (3) = 1.96, p = 0.580) or localisation (interaction tests across 
groups: delay F (3,97) = 1.08, p = 0.362; items F (3,97) = 1.17, p =
0.327) performance. However, there was an interaction between delay 
and the proportion of swap errors (interaction test across groups: F 
(3,97) = 2.90, p = 0.039), whereby symptomatic carriers showed larger 
differences compared to controls in the long-delay (difference in √swap 
error proportion = 0.203 [0.121, 0.285]; t (97) = 4.89; p < 0.001) than 
the short-delay (difference in √swap error proportion = 0.123 [0.058, 
0.187]; t (97) = 3.78; p < 0.001) (interaction tests for delay: symp-
tomatic carriers: F (1,97) = 8.27, p = 0.005; early PMCs: F (1,97) = 1.71, 
p = 0.194; late PMCs: F (1,97) = 0.01, p = 0.904). 
Although there was no significant interaction of group with block 
(interaction tests across groups: identification Х2 (3) = 3.09, p = 0.378; 
localisation F (3,97) = 1.92, p = 0.131; swaps F (3,97) = 2.06, p =
0.110), we investigated performance in the first block by delay, 
following Liang and colleagues finding of a significantly higher pro-
portion of swap errors in the PMC group than controls, in the first block 
long-delay condition (Liang et al., 2016). As was seen in the analysis 
combing both blocks, in block 1 symptomatic carriers showed larger 
differences compared to controls in the long-delay condition (difference 
in √swap error proportion = 0.159 [0.039, 0.279]; t (97) = 2.62; p =
0.010) than the short-delay (difference in √swap error proportion =
0.079 [-0.02, 0.179]; t (97) = 1.55; p = 0.125) (interaction test for delay 
Fig. 2. Cross-sectional adjusted mean performance by group (from model 
adjusted for age, sex and NART). A. Identification performance (across all 
conditions); B. Localisation error (across all conditions); C. Swap error pro-
portion across all conditions and by delay in block 1. Error bars show ± stan-
dard error of the mean. PMC = presymptomatic mutation carrier. * =
significant at p < 0.05; ** = significant at p < 0.01. 
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in block 1, symptomatic carriers: F (1,97) = 8.20, p = 0.005). No sig-
nificant differences emerged at a presymptomatic level for either delay 
in block 1 (Table 1, Fig. 2). 
Taken together, the cross-sectional findings presented here do not 
replicate entirely Liang and colleagues’ study (Liang et al., 2016). Spe-
cifically, while symptomatic participants showed a poorer performance 
for all metrics in both studies, PMCs (early or late) did not show evi-
dence for a greater swap error proportion in the longest-delay condition 
as reported previously (Liang et al., 2016). See the Supplementary Ma-
terials (section 2.4, Fig-e.5) for a direct comparison between the new 
participants and the cohort previously published by Liang and col-
leagues (Liang et al., 2016) and the Discussion for possible reasons for 
these differences. 
3.2. Longitudinal analysis for N = 48 
Forty-eight individuals completing at least two annual visits were 
included in the longitudinal analysis: 19 controls; 20 individuals who 
remained PMCs throughout the duration of the study: 12 early PMCs, 8 
late PMCs; 3 converters-participants who were late PMCs at baseline but 
had symptoms at their last follow-up visit and 6 symptomatic carriers. 
Considering all visits together, longer delay (1 vs 4s); higher memory 
load (3 vs 1 item); and block 1 (vs block 2) had significant effects on 
VSTM metrics resulting in worse: localisation, identification and swap 
error performance (greater error, poorer performance, see the Supple-
mentary Materials, section 2.3, for the effect size of delay, memory load 
and block on each VSTM metric). 
3.2.1. Rates of change in VSTM function 
3.2.1.1. Identification performance. Throughout the course of the study, 
there was little change over time in identification performance within 
controls and PMCs (Z = − 0.11, p = 0.913; early PMCs: Z = 0.19, p =
0.850; late PMC: Z = − 1.23, p = 0.217), whereas performance for 
symptomatic carriers decreased over time (Z = − 2.53, p = 0.011) (see 
Table 2 for the percentage odds of correct identification over time within 
each group). 
There was no significant difference in the rate of change of identi-
fication performance between either PMC group and controls (early 
PMCs: Z = 0.22, p = 0.830 vs the rate of change of controls, late PMCs: Z 
= − 0.85, p = 0.395 vs the rate of change of controls, see Table 2 for 
effect sizes), while symptomatic carriers showed a faster decline in 
identification performance over time (Z = − 2.10, p = 0.036 vs rate of 
change in controls, with 42.8 [2.5, 66.4] % lower odds of correct 
identification than controls at baseline decreasing to 64.7 [3.7, 80.2] % 
lower by year 3, Fig. 3A). 
There was no significant interactions on rates of change between 
group and item number, delay length or block so this metric was not 
investigated further (interaction test for change over time across all 
three groups: item: Х2 (3) = 2.64, p = 0.451; delay Х2 (3) = 2.08, p =
0.557; block: Х2 (3) = 2.90, p = 0.408). 
3.2.1.2. Localisation performance. Localisation performance generally 
stayed the same throughout the course of the study for controls (Z =
0.34, p = 0.737) and early PMCs (Z = 0.22, p = 0.826), whereas local-
isation error increased over time for late PMCs (Z = 2.55, p = 0.011) and 
symptomatic carriers (Z = 2.13, p = 0.033) reflecting a decrease in 
performance over time (see Table 2 for the adjusted percentage changes 
in localisation error over time within each group). 
Considering all task conditions together, late PMCs and symptomatic 
carriers showed a trend towards a faster rate of decline in localisation 
performance compared to controls (late PMCs: Z = 1.74, p = 0.082 vs the 
rate of change of controls and symptomatic carriers: Z = 1.84, p = 0.066 
vs the rate of change of controls). No differences in the rate of change 
were observed between early PMCs and controls (Z = − 0.07, p = 0.946) 
(see Table 2 for effect size differences between each patient group and 
controls). 
Both item number and delay length but not block, had a significant 
effect on differences in performance between groups, with differences 
from controls larger for longer delay and in the three item condition 
(overall interaction test for means across all three groups: items: Х2 (6) 
= 38.46, p < 0.001; delay: Х2 (6) = 20.99, p = 0.002; block Х2 (6) =
7.71, p = 0.260). 
There was a significant interaction between delay and group in the 
rate of change (interaction test for change over time across all three 
groups: Х2 (3) = 8.57, p = 0.036), whereby for the late PMC group in the 
4s delay, but not 1s delay condition (interaction test for change over 
time in late PMCs: Х2 (1) = 6.13, p = 0.013), late PMCs showed 
Table 2 
Rates of change in VSTM function per year. The first row indicates the change 
over time within each group (change/year). The second row compares the rate 





Adjusted mean [95% CI] Group difference [95% CI] 
(control as reference) 
Early PMCs 
(N = 12) 
Late PMCs 
(N = 11) 
Symptomatic 
carriers (N = 6) 
Identification performance: % change in odds of correct response 








NA 1.2 [-9.2, 
12.8] 




Localisation error: change in % error 






7.0 [0.6, 13.8]* 




6.5 [-0.4, 13.9] 






7.3 [0.5, 14.6]* 




6.9 [-0.5, 14.7] 






9.9 [1.7, 18.8]* 




9.0 [0.3, 18.5]* 






4.8 [-3.4, 13.6] 




4.7 [-3.9, 14.2] 
1-item 0.6 [-3.2, 
4.4] 




5.5 [-4.7, 16.9] 




5.0 [-5.9, 17.0] 






8.1 [-3.3, 20.8] 




7.1 [-4.9, 20.5] 
1-item, 4s 0.2 [-3.8, 
4.3] 




3.0 [-7.7, 15.0] 




2.8 [-8.6, 15.7] 
Swap error: change in √proportion 









− 0.016 [-0.043, 
0.011] 






− 0.015 [-0.045, 
0.014] 

















− 0.002 [-0.049, 
0.045] 
Adjusted mean difference in rate of change per year by group and compared to 
controls. CI= Confidence intervals; NA = not applicable; PMC = presymptom-
atic mutation carrier. Bold = significant; *: significant at p < 0.05. **: significant 
at p < 0.01; % change in odds calculated as (odds ratio-1)*100. 
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significantly greater increase in localisation error over time than was 
seen in the controls (4s, 1-item: Z = 2.02, p = 0.043 and 4s, 3-items: Z =
2.67, p = 0.008, see Table 2 for effect sizes). This interaction with delay 
was not seen for the other patient groups (interaction test for change 
over time: early PMCs: Х2 (1) = 2.40, p = 0.123; symptomatic carriers: 
Х2 (1) = 0.72, p = 0.396) and differences in rate of change between 
groups did not depend on the number of items or block (interaction test 
for change over time across all three groups: items Х2 (3) = 3.96, p =
0.266; block Х2 (3) = 2.50, p = 0.474), emphasizing that decline in 
localisation performance for late PMCs was specific to longer delays. 
This meant that a difference in localisation error between late PMCs and 
controls was apparent from 2 years after baseline, with the greatest 
difference in the 3-items, 4s delay condition (difference 11.0 [-10.0, 
36.8] % at baseline, increasing to 35.4 [5.4, 73.8] % at 3 years) (Fig. 3B). 
The early PMC group did not show differences from controls in the rate 
of change in localisation error in any condition (Table 2). Symptomatic 
carriers generally had a faster increase in localisation error than con-
trols, but this only reached statistical significance in the 3-items, 1s 
delay condition (Z = 2.02, p = 0.043, see Table 2 for effect sizes). 
3.2.1.3. Swap error performance. Swap error performance for all 
groups, generally stayed the same throughout the course of the study 
(controls: Z = − 0.08, p = 0.937; early PMCs: Z = − 1.20, p = 0.231; late 
PMCs: Z = 0.07, p = 0.943 and symptomatic carriers: Z = − 1.18, p =
0.237, see Table 2 for changes in √swap error proportion over time 
within each group). 
There was no difference in rate of change in swap error performance 
over time between either PMC groups and controls (early: Z = − 0.86, p 
= 0.389 vs the rate of change of controls, late: Z = 0.10, p = 0.917 vs the 
rate of change of controls, see Table 2 for effect size differences). 
Although symptomatic carriers made a greater proportion of swap errors 
than controls overall (test for mean difference in performance between 
groups: Х2 (2) = 20.47, p < 0.001; difference in √swap error proportion 
at baseline = 0.182 [0.093, 0.239], and at visit 3 = 0.135 [0.043, 
0.227]), there was no difference in the rate of change compared to 
controls (Z = − 1.02, p = 0.309, Fig. 3C) (see Table 2 for effect size 
differences between each patient group and controls). 
While there was only weak evidence that differences between groups 
in change over time in swaps were influenced by block and delay 
(interaction test for change over time across all three groups: block: Х2 
(3) = 6.59, p = 0.086; delay Х2 (3) = 0.62, p = 0.089), we specifically 
examined the 4s delay of block 1, following Liang and colleagues finding 
of higher swap errors in PMCs in this condition (Liang et al., 2016). 
There was a trend for a greater increase in swap error proportion over 
time for late PMCs compared to controls (Z = 1.65, p = 0.099 vs the rate 
of change of controls, see Table 2 for effect size), however this effect did 
not reach statistical significance. No difference in the rate of change vs 
controls was observed for early PMCs (Z = 0.21, p = 0.830). Despite 
having a higher proportion of swaps in the 4s delay of block 1 (test for 
mean difference in performance between groups: Х2 (2) = 15.32, p <
0.001; difference in √swap error proportion at baseline = 0.177 [0.086, 
0.264], and at visit 3 = 0.172 [0.054, 0.289]), symptomatic carriers 
showed no difference in rate of change compared to controls in this 
condition either (Z = − 0.07, p = 0.946) (see Table 2 for effect size 
differences). 
3.2.2. Relationship between VSTM performance and proximity to symptom 
onset 
3.2.2.1. Identification performance. There was no significant association 
between identification performance and EYO within FAD carriers 
(symptomatic and presymptomatic combined, Х2 (2) = 4.24, p = 0.120, 
Fig. 4A–C). Nonetheless, identification performance significantly 
decreased with AYO in the subgroup analysis of symptomatic carriers 
and converters (Х2 (2) = 15.78, p < 0.001) (Fig. 4B). The association 
with EYO did not differ by number of items (interaction test: Х2 (2) =
2.42, p = 0.298), delay length (interaction test: Х2 (2) = 0.70, p = 0.705) 
or block (interaction test: Х2 (2) = 1.12, p = 0.573). 
3.2.2.2. Localisation performance. Localisation error significantly 
increased with EYO in FAD mutation carriers (Х2 (2) = 7.46, p = 0.024). 
There was a significant interaction with item number (interaction test: 
Х2 (2) = 27.97, p < 0.001) and delay length (interaction test: Х2 (2) =
13.60, p = 0.001) such that the localisation deficit associated with closer 
proximity to onset was greater with high load and long delay (i.e. when 
the memory demands were greatest), but there was no interaction with 
block (interaction test: Х2 (2) = 2.54, p = 0.280). Results were therefore 
examined by item and delay. There was a significant increase in local-
isation error with less years to estimated onset for PMCs carriers (or 
more years post onset for symptomatic carriers) in both 3-item condi-
tions (1s delay: Х2 (2) = 6.64, p = 0.036; 4s delay: Х2 (2) = 12.94, p =
0.002) but not in the 1-item conditions (1s Х2 (2) = 2.42, p = 0.298; 4s 
Х2 (2) = 4.31, p = 0.116). The association was thus strongest in the 3- 
items, 4s delay condition (Fig. 4D), where a significant difference in 
mean localisation error between FAD carriers (presymptomatic and 
symptomatic) and controls was observed from 6 years before expected 
onset (20.1 [5.5, 41.0] %, Z = 2.62, p = 0.024). 
Localisation error also significantly increased with AYO within 
Fig. 3. Longitudinal adjusted estimated mean performance by group (from model adjusted for age at baseline, sex and NART). A. Identification performance 
(across all conditions). B. Localisation error performance for the 3-item, 4s delay condition. C. Swap error performance (across all conditions). PMC = presymp-
tomatic mutation carrier. Error bars indicate ± standard error by time from baseline visit. * = the rate of change between groups was statistically significant at p <
0.05 (control as reference); ** = the rate of change between groups was statistically significant at p < 0.01 (control as reference). 
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symptomatic carriers and converters (Х2 (2) = 30.15, p < 0.001) 
(Fig. 4E). 
3.2.2.3. Swap error proportion. There was no significant association 
between swap error proportion and EYO within FAD carriers (Х2 (2) =
4.20, p = 0.123, Fig. 4G) nor with AYO in the symptomatic group with 
converters (Х2 (2) = 0.29, p = 0.863, Fig. 4H). The association with EYO 
did not differ by delay length (interaction test: Х2 (2) = 3.75, p = 0.153) 
or block (interaction test: Х2 (2) = 3.58, p = 0.167). 
3.2.3. Longitudinal change of participants on traditional neuropsychology 
Following our findings of a faster rate of decline in localisation 
performance, we considered rates of change in traditional 
neuropsychology tasks. 
A significant difference between late PMCs and controls on the RMT 
words was observed approximately 1 year later than the presymptom-
atic changes observed in localisation performance (i.e. from 3 years after 
baseline), with 35.0 [45.6, 22.2] % greater rate of decline per year (Z =
− 4.71, p < 0.001, Fig. 5). 
A significant difference between controls and early PMC group was 
seen for RMT faces but in the opposite direction to that expected (early 
PMCs: 13.7 [1.0, 28.0] % greater increase in performance per year, Z =
2.12, p = 0.034). No further significant group differences emerged at a 
presymptomatic level. While verbal and performance IQ measures 
showed lower values for PMCs at baseline, there was no evidence for a 
faster rate of decline compared to controls (VIQ: early PMCs: 0.9 [-1.1, 
Fig. 4. Relationship between VSTM performance and proximity to symptom onset. Identification performance is presented across all task conditions; local-
isation error specifically for the 3-items, 4s delay condition (where the association was strongest) and swap error proportion across delays (by definition only assessed 
in the 3-items condition). Panels A., B., D., E., G. and H. show the predicted mean of each VSTM metric (from model adjusted for age, sex and NART) against EYO or 
AYO. Shaded area indicates 95% confidence intervals. Panels C., F. and I. shows the unadjusted raw data plotted against EYO for each VSTM metric with visits 
marked as dots and connected for each participant; note there is no scale on the x-axes to preserve participant anonymity. Converters are PMCs who transitioned into 
a symptomatic stage at their last visit. PMC = presymptomatic mutation carrier. EYO = estimated years to/from symptom onset; AYO = actual years to/from 
symptom onset. 
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2.9] points per year, Z = 0.85, p = 0.398; late PMCs: 0.0007 [-2.3, 2.3], 
Z = − 0.00, p = 1.000; PIQ: early PMCs: 0.07 [-1.5, 1.6] points per year, 
Z = 0.09, p = 0.930; late PMCs: 0.8 [-2.6, 1.0], Z = − 0.91, p = 0.363). 
Symptomatic carriers had a greater rate of decline than controls in: 
performance IQ (− 3.9 [-6.1, − 1.7] points per year, Z = − 3.45, p <
0.001); arithmetic (− 1.5 [-2.7, 0.3] points per year, Z = − 2.51, p =
0.012) and digit span backwards (66% greater decline per year, OR =
0.34 [0.13,0.91], Z = − 2.16, p = 0.031). 
4. Discussion 
4.1. Summary of findings 
The aim of this study was to investigate VSTM function over time 
using the “What was where?” task in a preclinical AD cohort like FAD. 
More specifically, we investigated a) differences in the rate of change 
between symptomatic and presymptomatic carriers compared to con-
trols; b) how VSTM varied continuously with proximity to onset and c) 
whether longitudinal decline was also seen in more traditional measures 
of neuropsychology. The main findings were that ‘late’ PMCs (within 8.5 
years of estimated onset) had a significantly faster rate of decline in 
localisation performance, which is in agreement with previous reports 
from our centre of impairment of PMCs on this measure using the same 
task. However, unlike the previous report (Liang et al., 2016) PMCs did 
not show a significant difference in the swap error proportion metric – a 
binary measure of misbinding. Importantly, differences in localisation 
performance from controls were observed in PMCs at least as early as 
changes in traditional neuropsychology measures of verbal episodic 
memory. Localisation performance was also the only VSTM metric to 
show a significant association with EYO with strongest effects observed 
in long delay conditions up to 6 years prior to estimated symptom onset. 
Other important findings include: symptomatic carriers showing a faster 
rate of decline in identification and localisation performance (though 
localisation effects were only found significant in one condition – 
3-items, 1s – most likely due to small numbers in this group) and iden-
tification performance decreasing with increasing AYO. 
Taken together, the finding of localisation deficits in FAD carriers – 
especially in those who were presymptomatic – indicates that the “What 
was where?” task may be sensitive in tracking preclinical decline. 
4.2. Preferential effect on localisation performance: what is this metric 
measuring? 
Relational binding in the “What was where?” task is conventionally 
measured using the ‘swap error proportion’ metric. In this approach, if 
the fractal is placed within 4.5 deg of another fractal in the memory 
array, it is considered ‘swapped’. While this pre-defined threshold 
measures misbinding as a proportion of error (in comparison to change- 
detection paradigms which evaluate accuracy between bound and un-
bound conditions but fail to quantify the error itself), the results pre-
sented in this paper suggest that the localisation performance metric, 
instead of the swap error proportion, may be more sensitive to pre-
clinical decline. The localisation performance metric measures the dis-
tance between the centre of the target object once placed in its 
remembered location and its true (original) location in the memory 
array after the correct fractal has been identified. Therefore, it could be 
argued that this metric indicates the resolution or quality of recall of the 
object’s identity bound to its exact location – with greater error indi-
cating less memory precision. Importantly, presymptomatic deficits 
were observed in both the localisation error and swap proportion met-
rics in Liang and colleagues report (Liang et al., 2016) and the findings 
presented here indicate that localisation performance could represent 
the resolution or accuracy of relational binding more sensitively than 
the swap error proportion – at least with regards to tracking presymp-
tomatic decline. 
In line with this proposal, in the same way that the ‘shape-only’ 
condition in a change-detection shape-colour conjunctive binding task, 
accounts for the ‘unbound’ condition; the identification performance 
metric here, may represent the ‘unbound’ condition. While a signifi-
cantly faster rate of decline in identification performance was also 
observed in symptomatic carriers in addition to localisation perfor-
mance, the deficit in late PMCs was specific to localisation performance. 
Furthermore, group differences between late PMCs and controls were 
reduced when comparing rates of change in the ‘nearest item control’ 
metric (see Supplementary Materials, section 2.2). This suggests that 
some of the imprecision in remembering the object’s identity and 
location, may be explained by a tendency to mislocalise the fractal to the 
location of another fractal (regardless of whether it was the target) and 
that the swap error proportion – being a binary metric – may not have 
been sensitive enough to detect this subtle change. 
The focus on localisation performance as a measure of relational 
binding accuracy is in line with more recent views of working memory 
models, specifically resource models, in which recall declines gradually 
and continuously with increasing number of items as resources are 
flexibly distributed (Bays and Husain, 2008; Wilken and Ma, 2004). 
Importantly, localisation precision decreased (the degree of error 
increased) when three fractals were presented in comparison to one. In 
this regard, it may be relevant to note a recent study by Weston and 
colleagues (Weston et al., 2020) showing higher mean diffusivity for 
PMCs than controls in the precuneus – a region important for mental or 
visuo-spatial imagery and closely related to working memory (Baddeley, 
2003). This emphasizes that quantifying precision in space (e.g. through 
a continuous measure like localisation performance), may be best suited 
to detect subtle cognitive changes in PMCs. Additionally, as these effects 
were predominant in long delay conditions, the impairment observed in 
late PMCs over time, may be related to a difficulty in maintenance 
processes. 
We speculate that our longitudinal findings may be explained by a 
‘unified account of hippocampal forgetting across short and long time-
scales’, proposed recently by Sadeh and Pertzov (2020) according to 
which the similarities between short (interval of a few seconds between 
study and test, e.g. STM or working memory paradigms) and long 
timescales (study-test intervals of several minutes to days/months) 
suggests that a single hippocampus-based mechanism underlies memory 
in both timescales. This contrasts the once prevailing view that the 
hippocampus (proposed to be one of the earliest regions affected by AD 
pathology by some (Chan et al., 2016; Fox et al., 1996; Liang et al., 
2017)) was exclusively involved in memory and forgetting over long 
timescales. We propose that a process similar to accelerated forgetting 
may provide an explanation for the deficits observed and that the pas-
sage of time may be a source of forgetting in PMCs. Accelerated 
forgetting refers to a long-term memory process whereby new material 
appears to be encoded and retained normally over periods of up to 30 
Fig. 5. Longitudinal estimated mean performance for RMT for words by 
group (from model adjusted for age at baseline, sex and NART). PMC =
presymptomatic mutation carrier; RMT = recognition memory test. Error bars 
indicate ± standard error by time from baseline visit. * = the rate of change 
between groups was statistically significant at p < 0.05 (control as reference). 
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min but is then forgotten at an abnormally rapid rate over the following 
hours to weeks (Weston et al., 2018). Analogously, our results suggest 
that the precision of localisation performance in VSTM for late PMCs, 
declined at an accelerated rate compared to controls. While the exact 
mechanism for this process is poorly understood, the hippocampus has 
been implicated in the formation and retention of memories (Squire, 
2009). Notably, previous reports from our centre have shown strong 
correlations between localisation performance and hippocampal volume 
(once adjusted for age, sex and total intracranial volume). Therefore, 
there may be processes specific to the hippocampus which underly this 
‘accelerated forgetting’ phenomenon across time-scales – though other 
reports have shown that atrophy in the entorhinal cortex precedes that 
in the hippocampus (Braak and Braak, 1991; Liang et al., 2017) and 
these topics are still under debate in the field of AD. 
4.3. Integrating VSTM results with previous literature 
Unlike reports from our centre by Liang and colleagues showing a 
higher proportion of swap errors in PMCs (Liang et al., 2016), 
cross-sectional deficits presented here were only observed in symp-
tomatic carriers. In addition, there was no difference in the rate of 
change of swap errors for any of the patient groups compared to con-
trols. While the separation of PMCs into ‘late’ and ‘early’ is novel, PMCs 
as a whole did not show a greater proportion of swap errors either (see 
Supplementary Materials, Fig-e5). 
A number of reasons may explain these differences. Firstly, differ-
ences in the characteristics of the PMCs sample in comparison to Liang 
and colleagues’ report (Liang et al., 2016) may have influenced results. 
The inclusion of more PMC participants (23 in our study vs 12 in Liang 
and colleagues’ and 6 additional mutations – 5 PSEN1 and 1 APP) meant 
that they were on average further from expected onset and had a broader 
range of EYO in comparison to Liang and colleagues’ report (mean EYO 
= 9.5 (SD 5.0) vs 8.5 (3.8)). This may have resulted in performance 
differences given that disease progression varies between genes (with 
PSEN1 mutation carriers more frequently presenting with non-amnestic 
cognitive symptoms than APP mutation carriers (Ryan et al., 2016; 
Scahill et al., 2013)) and even between mutations within the same gene 
(Pavisic et al., 2020b). Furthermore, late PMCs in our study had lower 
anxiety scores compared to controls (in both N = 99 and N = 48 sam-
ples) and this was not the case for Liang and colleagues’ PMC group (in 
which patients and controls had similar anxiety scores comparable to 
our control group (Liang et al., 2016)). While high anxiety levels have 
shown to negatively impact cognition (Okon-Singer et al., 2015) and 
visual working memory specifically (e.g. (Spalding et al., 2020)), im-
plications of low anxiety scores on cognition are complex and it is 
difficult to establish whether or not this could have carried some 
advantage for late PMCs performance especially in light of the reduced 
insight that may be observed sometimes in presymptomatic stages of 
FAD. Lastly, as a relatively accurate localisation is required for a 
response to count as a swap, swap errors may have been underrepre-
sented in our study (in both symptomatic and presymptomatic carriers) 
especially in light of the localisation error finding. The non-significant 
interaction between the rate of swap error proportion and delay in our 
longitudinal analysis was also surprising, yet the worsening localisation 
particularly for longer delays may have veiled this interaction too. 
A critical advantage of longitudinal studies over cross-sectional in-
vestigations is the ability to assess when changes occur. Recently, a 
proposal emerged suggesting that AD progressed in two stages: a sub- 
hippocampal phase characterised by impairments in context-free 
memory function such as those assessed by recognition tasks, followed 
by a hippocampal stage when impairments in context-rich memory 
functions (such as ‘associative memory’) are observed and which cor-
responds clinically to the stage at which cognitive impairment is evident 
(Parra, 2017). In this respect, it is relevant to note that the longitudinal 
performance of PMCs was significantly worse than controls both in the 
‘What was where?” task (arguably a context-rich memory function) and 
in the RMT for words and that changes in the localisation metric of the 
“What was where?” task were observed at least as early as changes in the 
RMT for words task. Decline in recognition memory tests have typically 
been associated with AD (e.g. (Diesfeldt, 1990)) and while most sensi-
tivity has been described in symptomatic AD, some reports suggest 
recognition discriminability for amnestic mild cognitive impairment 
patients with biomarker evidence of prodromal AD (Goldstein et al., 
2019). However, the relative sensitivities and multicomponent nature of 
each test certainly affect findings. For example, certain brain areas 
which are active during the episodic retrieval of recognition tests (e.g. 
the right anterior prefrontal cortex (Rugg et al., 1998) or the entorhinal 
cortex (Weston et al., 2016)), might also overlap with the neural cor-
relates of binding (frontal-parietal-MTL network for conjunctive binding 
and parietal-occipital-temporal networks for relational binding) (Jonin 
et al., 2019; Parra et al., 2015). Longitudinal imaging studies including 
physiological measures such as functional MRI, in preclinical AD pop-
ulations like presymptomatic FAD, are therefore needed to further 
establish which regions of the brain show significant deficits in pre-
clinical AD in comparison to controls and in which order. 
4.4. Limitations 
The current study has several limitations. Firstly, despite the 
increased sample size in comparison to the previous cross-sectional 
study (23 presymptomatic carriers in this study vs 12 presymptomatic 
carriers in (Liang et al., 2016)), this remains relatively small due to the 
low prevalence of FAD. Secondly, disease progression is complex and 
not well characterised in the literature, especially in FAD (Canevelli 
et al., 2014; Pavisic et al., 2020b; Ryman et al., 2014; Shea et al., 2016). 
As our study included mutation carriers from pedigrees with different 
PSEN1 and APP mutations, it is possible that by considering all FAD 
carriers together, the heterogeneity in the progression of the disease 
between genes and mutations may have affected our results. However, 
creating mutation-based subgroups would not have been possible due to 
issues around validity of modelling such small groups. Furthermore, 
‘late’ PMCs were a heterogenous group in that individuals’ EYO spanned 
within 8.5 years before expected onset; mean = − 5.8 (SD 1.8) years and 
these estimations are imprecise given the within-family variation in age 
at onset (Ryman et al., 2014). The exploratory analysis done separating 
PMCs by the median split has its limitations too, as some participants 
may lie close to each other in EYO but be classified into different groups. 
Yet, the investigation of VSTM performance and EYO in a continuous 
scale was presented as a complementary approach, partly for these 
reasons. Thirdly, the qualitative observation of VSTM performance in 
‘converters’ showed that for all VSTM metrics, performance did not 
follow a unique pattern once participants transitioned into a symp-
tomatic stage (for some participants, scores worsened while for others 
they remained stable). Reporting this substantial variability possibly 
resulting from the 100 trials completed by participants at every visit in 
addition to the limitations previously mentioned, is important as it raises 
novel considerations of the use of such tasks at an individual level. 
Lastly, our findings may also be explained by the attention and fronta-
l/executive demands of this task (with the localisation measure being 
particularly sensitive due to its continuous nature), rather than the 
visuo-spatial or memory aspects per se as well as differences in 
life-course factors (e.g. socio-economic status and occupation type), 
some of which have been shown to impact the onset and rate of cognitive 
decline in individuals with certain FAD mutations (e.g. (Aguirre-Ace-
vedo et al., 2016)). 
Taken together, the findings presented in this paper have important 
implications for the usefulness and reliability of this task especially as 
certain deficits in PMCs (e.g. swap errors) were not replicated. Notably, 
a recent FAD study by Norton and colleagues (Norton et al., 2020), 
found that the condition requiring conjunctive binding of colour and 
shape was not preferentially linked to tau (measured by positron emis-
sion tomography – PET) but rather that the non-binding “shape only” 
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condition showed a stronger relationship. This emphasizes that much 
remains to be understood about VSTM binding and that group studies 
comparing conjunctive and relational binding over time, will provide 
critical data on which processes are affected, at what stage and in which 
order. 
Longitudinally, the observation that deficits were seen in the late 
PMCs but not in early PMCs, raises important questions as to when the 
“What was where?” task – or relational binding as a cognitive function – 
may be sensitive to tracking preclinical decline in AD. In this regard it is 
worth noting that in the analysis of EYO as a continuous measure, def-
icits were seen up to 6 years before estimated age at symptom onset (the 
mean EYO of late PMCs). Future studies with greater sample sizes and a 
broader range of EYO, should investigate questions around usefulness 
and reliability further. 
4.5. Conclusions 
To the best of our knowledge, this is the first longitudinal investi-
gation on VSTM function in a preclinical sample like FAD over a period 
of many years. Our findings highlight that evaluating the degree of error 
on a continuous scale may be a sensitive measure of longitudinal decline 
in the presymptomatic stages of FAD. Analogous to the accelerated- 
forgetting hypothesis, we speculate a similar phenomenon may 
explain VSTM deficits, whereby the ability to spatially remember and 
retain a memory representation is forgotten with time at an ‘accelerated 
rate’ in presymptomatic FAD compared to controls. 
More broadly, these results merit further exploration particularly in 
light of the similarities between sporadic and familial AD and the 
importance of identifying and tracking individuals at-risk of developing 
AD as early as possible for intervention trials. Future longitudinal 
studies, which ideally administer conjunctive and relational binding 
tasks to the same sample, may wish to investigate correlation of per-
formance with functional outcomes, hippocampal volume or amyloid 
beta deposition, in order to further validate its use for screening and 
monitoring purposes in FAD and other preclinical AD populations more 
broadly. 
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